Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Chemotherapy in Unresectable Mesothelioma
NCT02899195Phase 2Completed
- Sponsor
- PrECOG
- Start
- Jun 2017
- Primary completion
- Feb 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in malignant pleural mesothelioma (MPM), sponsored by PrECOG. Primary endpoint: Overall Survival at 32 months. Started Jun 2017; status: completed.
02
Drugs
durvalumab
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT02899195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02899195.